Combined clearance of the navigation and drug delivery technologies enables Canadian neurosurgery centers to leverage the Company's flagship image-guidance workflow and advances ClearPoint Neuro's ...

ClearPoint Health (“ClearPoint”) is a medical stop-loss captive platform for small and mid-sized employers. ClearPoint’s platform empowers employers and benefit advisors to transition employee health ...

Reported fourth quarter revenue of $10.4 million, including $1.2 million of IRRAflow revenue, representing 34% overall growth and 19% year-over-year organic growth compared with the fourth quarter of ...

[Audio Gap] comments made on this call may include statements that are forward-looking within the meaning of securities laws. These forward-looking statements may include, without limitation, ...

William Wood, an analyst from B.Riley Financial, reiterated the Buy rating on ClearPoint Neuro (CLPT – Research Report). The associated price target is $10.00. William Wood’s rating is based on ...

2026 guidance is $52–56 million, but management excluded potential commercial revenue from certain rare‑disease partners after recent FDA guidance and also tempered expected European contribution ...

SOLANA BEACH, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the ...

“As we close the books on 2021, we reflect on a tremendous year for the Company as we have continued to execute and make progress across our four-pillar growth strategy,” commented Joe Burnett, ...

SAN DIEGO & BOSTON--(BUSINESS WIRE)--Clearpoint Agency, a women-owned, award-winning PR firm with offices in the San Diego and Boston areas, announced today that it has appointed Hilary McCarthy as ...

Combined clearance of the navigation and drug delivery technologies enables Canadian neurosurgery centers to leverage the Company's flagship image-guidance workflow and advances ClearPoint Neuro's ...

SOLANA BEACH, CA / ACCESS Newswire / March 17, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the ...